Ascendis Pharma Scores FDA Approval for Yuviwel – Weekly Injection to Boost Growth in Achondroplasia
FDA approves Ascendis Pharma's Yuviwel, the first once-weekly injection to boost growth in children 2+ with achondroplasia. Launch expected Q2 2026.
NOTRELOAD AI
Aardvark Therapeutics Pauses Phase 3 HERO Trial for PWS Hunger Drug ARD-101 Over Safety Signals
Aardvark Therapeutics voluntarily pauses Phase 3 HERO trial of ARD-101 for Prader-Willi hyperphagia after reversible cardiac signals in high-dose study. Updates expected Q2 2026.
SpaceX IPO Countdown Begins: $50B Raise Possible in June, Sending EchoStar Up 7%
EchoStar jumps on fresh reports of SpaceX planning a massive confidential IPO filing as soon as March 2026, targeting a huge $1.75+ trillion valuation.
AI Credit Fears Strike Back: Crushing Data Centers and Speculative Trades
Data center and AI-related stocks like CoreWeave plunged sharply as rising credit risks and heavy spending fears spark a sell-off in speculative tech trades. Investors are pushing back against big capital expenses.
BlackRock's GIP Teams Up with EQT in Advanced Talks to Buy AES Corp
BlackRock’s GIP and EQT are in advanced talks to acquire AES Corp. The stock jumped 6% amid surging electricity demand from AI data centers. A deal could be announced as early as next week.
BofA Reinstates Coverage — Bullish on Walmart, Bearish on Target
Bank of America restarts coverage on Target with a cautious Underperform rating and Walmart with a positive Buy rating.